In vivo murine melanoma experiments|Ex vivo experiments (single-cell suspensions from spleen or lymph nodes under flow cytometry analysis)

Tumor-Specific Cancer Vaccine Adjuvant Formulation

SUMMARY Many cancer vaccines fail due to insufficient CD8+ T cell targeting.  To save patient lives, oncologists need tumor-specific vaccines that increase CD8+ T cell response. The inventors developed and validated an intra-tumoral vaccine adjuvant for muringe melanoma.  They used a p(ManTLR7) glyco-polymer to chemically link to tumor cell binding… Read More